Cariprazine

Cariprazine (Vraylar) is an atypical antipsychotic used to treat schizophrenia, acute manic, mixed, and depressive episodes of bipolar I disorder, and, as an add-on to an antidepressant, major depressive disorder (MDD). It belongs to a small group of dopamine partial agonists, and it is set apart from most other antipsychotics by its preferential activity at the dopamine D3 receptor.

Cariprazine is taken as a capsule once a day. Because the drug and its active metabolites build up in the body over several weeks, its full clinical effect, and some of its side effects, can take weeks to appear after starting treatment or changing the dose.

Cariprazine is FDA-approved1 to treat:

• schizophrenia in adults and children 13 years of age and older
• acute manic or mixed episodes associated with bipolar I disorder in adults and children 10 years of age and older
• depressive episodes associated with bipolar I disorder (bipolar depression) in adults
• major depressive disorder (MDD) in adults, as an add-on to an antidepressant

Cariprazine is not approved for dementia-related psychosis in older adults, where antipsychotics raise the risk of death and stroke.

The exact mechanism of cariprazine is not fully known. Its effect is thought to come from a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. What makes cariprazine distinctive among antipsychotics is that it binds most strongly to the dopamine D3 receptor, with higher affinity there than at D2, a profile not shared by most other agents in the class.2

As a partial agonist, cariprazine can either dampen or support dopamine signaling depending on how much dopamine is already present, which is the basis for the "dopamine partial agonist" description it shares with aripiprazole and brexpiprazole.

Cariprazine forms two major active metabolites, desmethylcariprazine (DCAR) and didesmethylcariprazine (DDCAR), which have receptor-binding profiles similar to the parent drug and are considered pharmacologically equipotent to it. These long-lasting metabolites are the reason cariprazine behaves the way it does in the body.

Cariprazine has a long half-life, and its main active metabolite lasts far longer still. Based on the time to reach steady state, the half-life is about 2 to 4 days for cariprazine itself, about 1 to 2 days for DCAR, and roughly 1 to 3 weeks for DDCAR. Peak plasma levels are reached about 3 to 6 hours after a dose.

Because of this, blood levels keep rising for weeks after starting the medicine. Cariprazine and DCAR reach steady state at around week 1 to week 2, while DDCAR approaches steady state later, at around week 4 to week 8. After stopping cariprazine, DDCAR concentrations fall by about half roughly a week after the last dose, and the metabolite can still be detected up to 8 weeks after a single dose.

This slow build-up and clearance is why new side effects can appear several weeks into treatment or after a dose increase, and why prescribers monitor response for weeks after each change rather than expecting an immediate result.

Cariprazine is an atypical antipsychotic, also called a second-generation antipsychotic. Within that class, it is a dopamine and serotonin partial agonist, one of a small group of agents such as aripiprazole and brexpiprazole that are sometimes grouped as third-generation antipsychotics because they modulate dopamine rather than simply block it.3

Cariprazine carries boxed warnings, the most serious type of FDA warning:

• Increased risk of death in older adults with dementia-related psychosis. Cariprazine is not approved for this use.
• Increased risk of suicidal thoughts and behaviors. Cariprazine and the antidepressants it is combined with for MDD can increase suicidal thoughts and actions in people 24 years of age and younger, especially early in treatment or when the dose changes.

Cariprazine also has warnings for neuroleptic malignant syndrome, tardive dyskinesia, late-occurring adverse reactions, metabolic changes (high blood sugar and diabetes, changes in cholesterol and triglycerides, and weight gain), low white blood cell counts, orthostatic hypotension and fainting (syncope), falls, seizures, effects on body temperature control, difficulty swallowing, and impaired judgment or motor skills.

No. Cariprazine is not a controlled substance. It has not been systematically studied for abuse potential or physical dependence.

Not yet. As of 2026, there is no FDA-approved generic version of cariprazine in the United States, and it is available only as the brand Vraylar. Based on current patent protection, the earliest generic entry is estimated to be around 2029. Outside the United States, cariprazine is sold in Europe under the brand name Reagila.

Cariprazine is an antipsychotic, not a lithium-type or anticonvulsant mood stabilizer. It is, however, used across the mood states of bipolar I disorder, treating manic, mixed, and depressive episodes, so it is sometimes described in a mood-stabilizing role even though it belongs to a different drug class.

Some improvement may be seen within the first couple of weeks, but it can take several weeks of regular use to feel the full benefit. Because of the long half-life of cariprazine and its active metabolites, the full effect of any dose is not reached quickly, and a dose change is not fully reflected in the body for several weeks. Keep taking it as prescribed and tell your doctor if symptoms do not improve.

You should not take cariprazine if you are allergic to it. Reported hypersensitivity reactions have ranged from rash, itching, and hives to swelling of the tongue, lips, or face. Before starting, tell your doctor if you have heart disease or high blood pressure, a history of stroke or blood clots, high cholesterol or triglycerides, diabetes or high blood sugar, liver or kidney disease, a low white blood cell count, or a history of seizures, and if you are pregnant, planning to become pregnant, or breastfeeding.

The most common side effects of cariprazine are movement-related. In clinical trials, the reactions reported most often (in at least 5% of adults and at least twice as often as placebo) were extrapyramidal symptoms, which include tremors, muscle stiffness, and slowed or difficult movement, and akathisia, a sense of restlessness and an inability to sit still.

Which side effects appear most often depends on the condition treated, but across indications they also include nausea, vomiting, indigestion, constipation, sleepiness, trouble sleeping, fatigue, increased appetite, dizziness, and restlessness. Because cariprazine accumulates over weeks, some effects may not appear until well after starting the medicine or increasing the dose.

Cariprazine capsules are taken by mouth once a day, with or without food. The dose depends on the condition being treated. The starting and target doses below are for adults.

• Schizophrenia: start at 1.5 mg once daily; may increase to 3 mg on Day 2; usual range 1.5 mg to 6 mg once daily; maximum 6 mg a day
• Bipolar I manic or mixed episodes: start at 1.5 mg once daily; increase to 3 mg on Day 2; usual range 3 mg to 6 mg once daily; maximum 6 mg a day
• Bipolar depression: start at 1.5 mg once daily; may increase to 3 mg on Day 15; maximum 3 mg a day
• Add-on for MDD: start at 1.5 mg once daily; may increase to 3 mg on Day 15; maximum 3 mg a day

Doses above 6 mg a day have not been shown to add enough benefit to outweigh the higher rate of dose-related side effects. Lower starting doses apply to children and to people taking a strong or moderate CYP3A4 inhibitor. For full titration schedules, pediatric dosing, and dose adjustments, see the detailed dosage information.

Cariprazine is broken down mainly by the CYP3A4 enzyme, so drugs that affect CYP3A4 change how much cariprazine is in the body:

• Strong and moderate CYP3A4 inhibitors raise cariprazine levels, so the cariprazine dose is reduced when they are used together.
• CYP3A4 inducers are not recommended with cariprazine, because their effect on cariprazine levels has not been established.

Taking cariprazine with other medicines that cause drowsiness or slow breathing, such as opioids, sedatives, or muscle relaxants, can be dangerous. Many other prescription drugs, over-the-counter medicines, vitamins, and herbal products can interact with cariprazine, so tell your doctor about everything you take.